TXNRD1 and neoplasm: Thus far the data has shown causal links (1) between TXNRD1 inhibitor treatment and increased B16F10 tumor burden, (2) between TXNRD1 inhibitor treatment and increased Treg expansion in mice and human cultures, (3) between a mechanistic byproduct of TXNRD1 inhibitor treatment (H2O2) and increased Treg expansion, and (4) between biological producers of H2O2, (B cells and DCs) and increased B16F10 tumor burden.